Seelos Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 73.53 million compared to USD 66.05 million a year ago. Basic loss per share from continuing operations was USD 20.7 compared to USD 21.9 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2902 USD | +19.72% | +0.42% | -79.12% |
1st Jan change | Capi. | |
---|---|---|
-79.12% | 3.32M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- SEEL Stock
- News Seelos Therapeutics, Inc.
- Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022